http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-050099-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dfae81468523c4a7e635145a1bfe2359 |
| filingDate | 2005-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a54ca738421f3e5bdd6074b06e63f734 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba983d7624c930efeb1ca32ea67c9b21 |
| publicationDate | 2006-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-050099-A1 |
| titleOfInvention | USE OF PEPTIDIC COMPOUNDS FOR PROFILAXIS AND THE TREATMENT OF CHRONIC HEADACHE |
| abstract | Claim 1: Use of a compound having the formula (1), wherein R is hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl, aryl (lower alkyl), heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl , lower cycloalkyl or (lower cycloalkyl) lower alkyl, and R is unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R1 is hydrogen or lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl, heterocyclyl, lower cycloalkyl, (lower cycloalkyl) lower alkyl, each unsubstituted or substituted with at least one electron donor group and / or at least one electron acceptor group; R2 and R3 are independently hydrogen, lower alkyl, lower alkenyl, lower alkynyl, aryl (lower alkyl), aryl, halo, heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl, lower cycloalkyl, (lower cycloalkyl) lower alkyl or ZY, where R2 and R3 may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and where R2 and R3 heterocyclyl is furyl, thienyl, pyrazolyl, pyrrolyl, methylpyrrolyl, imidazolyl, indolyl, triazolyl, oxazolyl, isothiazolyl, isoxazolyl, piperidyl, pyrrolinyl, piperazinyl, quinolyl, triazolyl, tetrazolyl, isoquinolyl, benzofuryl, benzothienyl, morpholinyl, benzoxazolyl, tetrahydrofuryl, pyranyl, indazolyl, purinyl, indolinyl, pyrazolindinyl, imidazolinyl, imidazolindinyl, pyrrolidinyl, furazanyl, N-methylindolyl, methylfuryl, pyridazinyl, pyrimidinyl, pyrazinyl, pyridyl, azyridyl, azydyl, azetyl, azydyl, azethyl, azethyl, azethyl, ethyloid, azydyl, azydyl, ethyloid, azydyl, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloid, azydyl, ethyloxy, nyl, ethyloxyl, ethyloxy, ethyloxy, ethyloxyl, azytyl, ethyloxy, ethyloxy, ethyloxy, azexyl, ethyloxyl, ethyloxy, ethyloxy, ethoxy; in the heterocyclyl, an N-oxide thereof; Z is O, S, S (O) a, NR4, NR6 'or PR4 or a chemical bond; Y is hydrogen, lower alkyl, aryl, aryl (lower alkyl); lower alkenyl, lower alkynyl, halo, heterocyclyl, heterocyclyl (lower alkyl), (lower alkyl) heterocyclyl and Y may be unsubstituted or substituted with at least one electron donor group and / or at least one electron acceptor group, where heterocyclyl it has the same meaning as R2 or R3 and with the proviso that when Y is halo, then Z is a chemical bond; or Z and Y taken together as ZY are NR4NR5R7, NR4OR5, ONR4R7, OPR4R5, PR4OR5, SNR4R7, NR4SR7, SPR4R5, PR4SR7, NR4PR5R6, PR4NR5R7 or N + R5R6R7, or a formula (2); R6 'is hydrogen, lower alkyl, lower alkenyl or lower alkynyl which may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R4, R5 and R6 are independently hydrogen, lower alkyl, aryl, aryl (lower alkyl), lower alkenyl or lower alkynyl, where R4, R5 and R6 can independently be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and R7 is R6 or COOR8 or COR8, R7 being able to be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; R8 is hydrogen or lower alkyl, or aryl (lower alkyl), and the aryl or alkyl group may be unsubstituted or substituted with at least one electron acceptor group and / or at least one electron donor group; and n is 1-4; and a is 1-3; or of a pharmaceutically acceptable salt thereof, characterized in that said use is for the preparation of a pharmaceutical composition useful for the prevention, relief and / or treatment of headache and / or painful conditions associated with and / or caused by propagated cortical depression (CSD). Claim 2: Use according to claim 1, characterized in that the headache is chronic headache. Claim 3: Use according to claims 1 or 2, characterized in that the headache is migraine. Claim 4: Use according to claim 3, characterized in that the use is for the manufacture of a medicament for the treatment of acute migraine. |
| priorityDate | 2005-08-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.